Vor Biopharma announces partner RemeGen wins two China approvals for telitacicept drug

Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• high

  RemeGen received conditional approval from China's NMPA to sell telitacicept for IgA nephropathy, a kidney disease. Conditional approval allows commercialization while confirmatory studies continue.

  Item 8.01 view on EDGAR →
• high

  RemeGen also received full NMPA approval for telitacicept to treat Sjögren's disease, an autoimmune disorder. This is the drug's second approved indication in China.

  Item 8.01 view on EDGAR →
• medium

  The dual approvals expand telitacicept's commercial opportunity in China and may generate milestone payments or royalties for Vor depending on partnership terms.

  8-K: Partner milestone verify on EDGAR →